Abstract 929P
Background
Pembrolizumab plus platinum and fluorouracil is the standard first-line treatment in patients with recurrent/ metastatic head and neck squamous-cell carcinoma (R/M HNSCC). However, there is no relevant data on nasal cavity and paranasal sinuses in KN-048. As the first prospective study of immunotherapy combined with chemotherapy in the treatment of SCC of nasal cavity and paranasal sinuses, it aims to verify its efficacy.
Methods
Patients with untreated R/M SCC of nasal cavity and paranasal sinuses and with ≥1 measurable lesion according to RECIST 1.1 were included. Patients received pembro 200mg, nab-paclitaxel 260mg/m2 plus cisplatin 75 mg/m2 or carboplatin AUC5 on day 1 every 21 days for up to six cycles followed by pembro maintenance therapy until progression or unacceptable toxicity or 35 cycles, whichever occurred first. The primary endpoint were ORR and PFS. Secondary endpoints were safety, DCR and OS.
Results
From August 26 2021 until March 3 2023, 16 patients were enrolled. The baseline characteristics are shown in the table. 1 patient with SD after 4 cycles of treatment was not treated for COVID-19. The ORR was 50% and 1 (5%) patient was CR (also this patient's CPS<1). The DCR was 100%. Median follow-up was 10.7 months, the median PFS and the median OS were not reached, and median Time of Treatment (TOT) was 7.7 months (2.1-20.3). Currently, only 1 patient who had achieved objective response has shown disease progression, and mTOT was 8.55 months (4.6-20.3). Grade 3 and 4 TRAEs reached 70%, and mainly come from chemotherapy-related neutropenia. 1 patient with grade 3 thrombocytopenia. Thyroid dysfunction is the most common irAEs. There was no TRAEs leading to treatment discontinuation.
Table: 929P
Patient characteristic | N=16 n(%) | |
Age, median (range), years | 61 (22-69) | |
Gender (male / female) | 12/4 | |
Primary tumor | nasal cavity | 5 (31.3) |
maxillary sinus | 11 (68.7) | |
Stage | IVA | 9 (56.3) |
IVB | 2 (12.5) | |
IVC | 5 (31.2) | |
PD-L1 combined positive score | <1 | 2 (12.5) |
1-19 | 4 (25.0) | |
≥20 | 8 (50.0) | |
unknow | 2 (12.5) | |
Disease condition | distant metastatic disease | 2 (12.5) |
local disease | 10 (62.5) | |
distant and local disease | 4 (25.0) |
Conclusions
Pembrolizumab plus nab-paclitaxel and platinum shows encouraging antitumor activity accompanied with a manageable side effect profile in untreated R/M SCC of the nasal cavity and paranasal sinuses patients.
Clinical trial identification
This study is registered at Chinese Clinical Trial Registry, number ChiCTR2200057343, and the release date is March 9, 2022.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
889P - CT-based radiomics models to predict progression in locally advanced head and neck cancer treated with definitive chemoradiation
Presenter: Gema Bruixola
Session: Poster session 12
890P - Real-world survival outcomes and survival risk factors in elderly patients with locally advanced squamous cell carcinoma of the head and neck
Presenter: Nabil Saba
Session: Poster session 12
891P - Changing landscape of head and neck squamous cell carcinoma (HNSCC) treatment and survival in Thailand: A 13-year multicenter retrospective study of 6,319 patients
Presenter: Nuttapong Ngamphaiboon
Session: Poster session 12
892P - Real-world data validation of university of San Diego nomogram for the prediction of benefit of intensive treatment for locoregionally advanced head and neck cancer
Presenter: Javier Caballero Daroqui
Session: Poster session 12
893P - Tumor node stage shift following leukocyte interleukin injection neoadjuvant extends overall survival in treatment-naïve locally advanced oral cavity/soft palate squamous cell carcinoma
Presenter: Jozsef Timar
Session: Poster session 12
894P - Is pathological complete response (PCR) a surrogate endpoint of overall survival in patients with technically unresectable oral cavity cancers? A real-world data study of 900 plus patients
Presenter: Shatabdi Chakraborty
Session: Poster session 12
896P - Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas
Presenter: Kai Wang
Session: Poster session 12
897P - Nanosomal docetaxel lipid suspension (NDLS) or docetaxel based neoadjuvant therapy in Head and neck squamous cell carcinoma: Post hoc analysis of a prospective, randomized study
Presenter: Darshit Shah
Session: Poster session 12
898P - Meta-analysis of two placebo-controlled trials of avasopasem manganese (AVA) in patients with locally advanced, head & neck cancer (LAHNC)
Presenter: Neal Dunlap
Session: Poster session 12